Skip to main content
PMC home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1982 Dec 11;285(6356):1697–1699. doi: 10.1136/bmj.285.6356.1697

Converting-enzyme inhibitor enalapril (MK421) in treatment of hypertension with renal artery stenosis.

G P Hodsman, J J Brown, D L Davies, R Fraser, A F Lever, J J Morton, G D Murray, J I Robertson
PMCID: PMC1500652  PMID: 6293638

Abstract

Enalapril maleate (MK421), a new inhibitor of angiotensin converting enzyme, in single daily doses of 1.25-40 mg was assessed in five patients with hypertension and renal artery stenosis. Only small falls in plasma angiotensin II concentrations were seen at doses less than 10 mg; even with 10 and 20 mg, angiotensin II concentrations had risen again 24 hours from the last dose. During long-term treatment with 10-40 mg daily all patients achieved good blood-pressure control. No significant changes of body sodium or potassium values were seen. The drug was well tolerated with no serious side effects. These findings are evidence of the efficacy and acceptability of enalapril in the medical management of hypertension with renal artery stenosis.

Full text

PDF
1697

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkinson A. B., Brown J. J., Cumming A. M., Fraser R., Lever A. F., Leckie B. J., Morton J. J., Robertson J. I. Captopril in renovascular hypertension: long-term use in predicting surgical outcome. Br Med J (Clin Res Ed) 1982 Mar 6;284(6317):689–693. doi: 10.1136/bmj.284.6317.689. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Atkinson A. B., Cumming A. M., Brown J. J., Fraser R., Leckie B., Lever A. F., Morton J. J., Robertson J. I. Captopril treatment: inter-dose variations in renin, angiotensins I and II, aldosterone and blood pressure. Br J Clin Pharmacol. 1982 Jun;13(6):855–858. doi: 10.1111/j.1365-2125.1982.tb01878.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Atkinson A. B., Morton J. J., Brown J. J., Davies D. L., Fraser R., Kelly P., Leckie B., Lever A. F., Robertson J. I. Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition. Br Heart J. 1980 Sep;44(3):290–296. doi: 10.1136/hrt.44.3.290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boddy K., King P. C., Tothill P., Strong J. A. Measurement of total body potassium with a shadow shield whole-body counter: calibration and errors. Phys Med Biol. 1971 Apr;16(2):275–282. doi: 10.1088/0031-9155/16/2/310. [DOI] [PubMed] [Google Scholar]
  5. Brown J. J., Casals-Stenzel J., Cumming A. M., Davies D. L., Fraser R., Lever A. F., Morton J. J., Semple P. F., Tree M., Robertson J. I. Angiotensin II, aldosterone and arterial pressure: a quantitative approach. Arthur C. Corcoran Memorial Lecture. Hypertension. 1979 May-Jun;1(3):159–179. doi: 10.1161/01.hyp.1.3.159. [DOI] [PubMed] [Google Scholar]
  6. Davies D. L., Robertson J. W. Simultaneous measurement of total exchangeable potassium and sodium using 43 K and 24 Na. Metabolism. 1973 Feb;22(2):133–137. doi: 10.1016/0026-0495(73)90263-1. [DOI] [PubMed] [Google Scholar]
  7. Fraser R., Guest S., Young J. A comparison of double-isotope derivative and radioimmunological estimation of plasma aldosterone concentration in man. Clin Sci Mol Med. 1973 Sep;45(3):411–415. doi: 10.1042/cs0450411. [DOI] [PubMed] [Google Scholar]
  8. Gross D. M., Sweet C. S., Ulm E. H., Backlund E. P., Morris A. A., Weitz D., Bohn D. L., Wenger H. C., Vassil T. C., Stone C. A. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. J Pharmacol Exp Ther. 1981 Mar;216(3):552–557. [PubMed] [Google Scholar]
  9. Heel R. C., Brogden R. N., Speight T. M., Avery G. S. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs. 1980 Dec;20(6):409–452. doi: 10.2165/00003495-198020060-00001. [DOI] [PubMed] [Google Scholar]
  10. MacGregor G. A., Markandu N. D., Bayliss J., Roulston J. E., Squires M., Morton J. J. Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): evidence for role of renin system in normotensive subjects. Br Med J (Clin Res Ed) 1981 Aug 8;283(6288):401–403. doi: 10.1136/bmj.283.6288.401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mackay A., Eadie A. S., Cumming A. M., Graham A. G., Adams F. G., Horton P. W. Assessment of total and divided renal plasma flow by 123I-hippuran renography. Kidney Int. 1981 Jan;19(1):49–57. doi: 10.1038/ki.1981.6. [DOI] [PubMed] [Google Scholar]
  12. Patchett A. A., Harris E., Tristram E. W., Wyvratt M. J., Wu M. T., Taub D., Peterson E. R., Ikeler T. J., ten Broeke J., Payne L. G. A new class of angiotensin-converting enzyme inhibitors. Nature. 1980 Nov 20;288(5788):280–283. doi: 10.1038/288280a0. [DOI] [PubMed] [Google Scholar]
  13. Williams E. D., Boddy K., Harvey I., Haywood J. K. Calibration and evaluation of a system of total body in vivo activation analysis using 14 MeV neutrons. Phys Med Biol. 1978 May;23(3):405–415. doi: 10.1088/0031-9155/23/3/004. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES